Bavarian Nordic vaccine helps prolong life in prostate cancer trial

(Reuters) – An experimental therapeutic vaccine from Danish drugmaker Bavarian Nordic helped significantly extend survival in patients with advanced prostate cancer, according to results of a small early-stage trial conducted by the U.S. National Cancer Institute.

—> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *